Cheryl Lubbert, CEO of Reverba Global, Named 2026 HBA Luminary Award Honoree

Cheryl Lubbert, CEO of Reverba Global, has been named a 2026 Luminary Award honoree by the Healthcare Businesswomen’s Association. The recognition reflects Cheryl’s leadership in advancing scientific engagement and patient-centered innovation, alongside a sustained commitment to mentoring and developing women across the healthcare industry.

Cheryl Lubbert, CEO of Reverba Global, recognized as a 2026 HBA Luminary by the Healthcare Businesswomen’s Association.

Recognition honors transformative leadership in advancing scientific engagement, tech-enabled solutions and patient-centered innovation

SEATTLE, WA — Reverba Global, a leader in tech-enabled scientific engagement for the biopharmaceutical industry, today announced that CEO Cheryl Lubbert has been named a recipient of the prestigious Luminary Award from the Healthcare Businesswomen’s Association (HBA). The award recognizes senior executives who drive meaningful impact in healthcare.

Lubbert is being recognized for her decades-long leadership in advancing how the industry connects with the people it serves across the healthcare ecosystem—transforming patient engagement into a strategic, insight-driven discipline to drive better health outcomes.

With more than 30 years of experience across healthcare and biopharmaceuticals, Lubbert has held leadership roles at companies including Abbott, Amgen, Immunex, and Bristol-Myers Squibb. Her career has been defined by building new models for engagement designed to serve both patients, healthcare professionals and payers.

Under her leadership, Reverba Global has expanded its capabilities across clinical, medical, and commercial functions, supporting global biopharmaceutical organizations in delivering compliant, data-driven engagement strategies.

Central to this mission is the development of the Patient Experience Engine, an operational system that combines more than 20 years of patient engagement with compliance expertise, deep scientific knowledge, and proprietary responsive, scalable technology. This platform empowers biopharmaceutical companies to build lasting relationships and activate patients at scale. Services including ReverbaBRIDGE® and ClinOps GPS™ support this model, ensuring alignment across organizations and stakeholders, providing continuity across the entire product lifecycle.

“Being recognized by the HBA is incredibly meaningful, not just personally, but for what it represents,” said Lubbert. “The biopharmaceutical industry is at a pivotal moment. The expectations for how we engage with patients, providers, and communities are higher than ever. Progress requires not only innovation, but a commitment to listening, learning, and building systems that reflect the realities of the people we serve.”

The HBA Luminary Award is one of the organization’s highest honors, celebrating leaders who are not only accomplished in their careers, but who actively foster the advancement of women in healthcare through relationship building, mentorship, and advocacy.

Lubbert’s connection to the HBA spans decades—she was named an HBA Rising Star during her time at Abbott, has served as an HBA mentor, and has contributed as a member of advisory boards supporting the organization’s mission to advance women in healthcare.

Lubbert will be honored at the 2026 HBA Global Ascension Leadership Experience, where industry leaders from across the globe will gather to recognize this year’s Award recipients.

About Reverba Global
Reverba Global (formerly Health Perspectives Group) is a scientific engagement company that empowers biopharmaceutical companies to connect with patients and healthcare providers to improve health outcomes. Reverba Global’s Patient Experience Engine combines more than 20 years of patient engagement with proprietary scalable technology, compliance expertise and deep scientific knowledge to deliver real-time insights, from discovery through commercialization. Learn more at reverba.com.


The Latest

  • What Gets Measured Gets Funded. But Is Patient Engagement Driving Better Outcomes?
    What Gets Measured Gets Funded. But Is Patient Engagement Driving Better Outcomes?

    Patient engagement is being measured more often, but metrics alone do not show why people participate, stay engaged, or report satisfaction. The more important question is what those measures reveal…

  • Why Pharma Is Rethinking Stakeholder Engagement Across the Product Lifecycle
    Why Pharma Is Rethinking Stakeholder Engagement Across the Product Lifecycle

    From trial recruitment to scientific exchange and patient support, stakeholder engagement cuts across clinical development, medical affairs, and commercialization. In partnership with Pharmaceutical Executive, Reverba Global has launched a new…

  • At Patients as Partners EU: From Insight to Measurable, Scalable Impact—What’s Next for Patient Engagement
    At Patients as Partners EU: From Insight to Measurable, Scalable Impact—What’s Next for Patient Engagement

    Key takeaways from Patients as Partners EU on measuring patient engagement, operationalizing patient experience data, scaling engagement programs, and translating patient insight into measurable outcomes.